Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate…
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate…
Sign in to your account